Breast Cancer: Key Insights on T-DXd Treatment and Patient Education

Saturday, 28 September 2024, 11:20

Breast cancer treatment with trastuzumab deruxtecan (T-DXd) requires nursing vigilance. Nurses must counsel patients on anti-emetics, hair loss, and the risk of interstitial lung disease. Understanding these factors is crucial for optimizing patient care during breast cancer therapy.
Oncnursingnews
Breast Cancer: Key Insights on T-DXd Treatment and Patient Education

Understanding Trastuzumab Deruxtecan (T-DXd) in Breast Cancer Treatment

Before starting a patient on trastuzumab deruxtecan for breast cancer, a nurse's role is critical in discussing potential adverse effects and necessary preparations.

Key Counseling Areas for Nurses

  • Anti-emetic Use: Discuss antiemetic regimens to mitigate nausea and vomiting.
  • Hair Loss: Educate patients about the possibility of hair loss (25-30% risk).
  • Interstitial Lung Disease: Explain the symptoms such as shortness of breath and cough.

Nurses should ensure that patients and their families are aware of signs of interstitial lung disease to manage any complications promptly.


Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest and most reliable health updates. Stay informed and enhance your wellness knowledge effortlessly.

Subscribe